/PRNewswire/ SIMCERE PHARMA (HK.2096), an innovation and R&D-driven pharmaceutical company with a mission of "providing today s patients with medicines of.
HONG KONG, April 7, 2022 /PRNewswire/ SIMCERE PHARMA (HK.2096), an innovation and R&D-driven pharmaceutical company with a mission of "providing today's patients with medicines of the future"
DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous28.02.2022 / 01:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Dis.
Search jobs 28-Jun-2021 Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer s Disease in Greater China
DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Agreement
29.06.2021 / 01:03
The issuer is solely responsible for the content of this announcement.
Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer s Disease in Greater China
Halle (Saale)/Munich, Germany and Nanjing, China, June 29, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines and Simcere Pharmaceutical Group Ltd (HKEX: 2096) (Simcere) today announced that they have entered into a strategic regional licensin